Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker ...
Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...
With two on-label agents now available, the panel turns to what actually drives the choice between them, noting how recently ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
As treatment options for Parkinson disease (PD) continue to expand, clinicians increasingly have to consider when patients ...
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of ...
Lundbeck recently announced that its Lu AF28996, an investigational oral prodrug of a D1-like/D2-like dopamine receptor agonist, was associated with increases in good ON-time and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results